Parkinson's Disease: A Review from Pathophysiology to Treatment.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing disease mechanisms and pharmacological treatments without systematic search methodology.
PubMed 31686637 · doi:10.2174/1389557519666191104110908
What was done
This paper is a narrative review summarizing the epidemiological features, pathophysiology, clinical motor symptoms, diagnostic approach, and standard pharmacological treatment strategies for Parkinson's disease.
What was found
The abstract reports that Parkinson's disease affects approximately 1.5% to 2.0% of the elderly population over 60 years and 4% of those over 80 years, with a higher prevalence in men. Pathophysiology is driven by necrosis of dopaminergic neurons in the substantia nigra, reduced synaptic dopamine, MAO-B-mediated dopamine degradation, glutamate accumulation, oxidative stress, and excitotoxicity. Diagnosis relies on evaluating motor features (rigidity, bradykinesia, tremor, postural instability) due to the absence of confirmatory laboratory tests, biomarkers, or imaging studies. Pharmacological management is non-curative and relies on levodopa, COMT inhibitors, anticholinergic agents, dopamine agonists, and MAO-B inhibitors.
Why it matters
It provides a concise synthesis of established mechanisms and conventional symptomatic pharmacotherapies for Parkinson's disease.
Limits
As a narrative review, it presents no original empirical data, systematic search criteria, or quantitative synthesis. Non-motor symptoms, non-pharmacological interventions, surgical options, and long-term drug-induced adverse effects are not addressed in the abstract.
Cited by
- supports Dopamine neurons in the substantia nigra are critical for generating smooth movement and degenerate in Parkinson's disease, causing elevated resting tremor and difficulty initiating movement.